Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).
When your blood doesn't have enough healthy red blood cells or have enough hemoglobin, you can tire quickly or feel weak. This condition is called anemia. The fatigue that comes with anemia can lead to a decreased quality of life. Some fatigue is not related to anemia. Anemia has three broad causes; blood loss, decreased blood cell production and increased blood cell destruction. The first two are the most relevant for GIST patients.
Stivarga comes in 40 mg tablets. Once opened, it must be used within 28 days. Stivarga must be stored in the bottle that it comes in, the desiccant must remain in the bottle; keep bottle tightly sealed. Do not store in a daily or weekly pill box.
Many new cancer drugs are entering clinical practice and clinical trials. Many GIST patients are no longer responding to Gleevec or Sutent and thus are looking for clinical trials. Understanding strategies and grouping these new drugs into classes with other similar drugs may help patients understand some of their choices.
You may not have noticed, but the clinical trials section of the website has changed dramatically in the last month. This section of the website is now database-driven and has a lot more information.
The new treatment uses T cells, a type of immune cell that are taken from the patient’s body, genetically modified and then reinfused into the patient. These modified T cells are called chimeric antigen receptor (CAR) T cells. In previous trials with these modified T cells, tumor responses have been modest and they did not persist for long enough after being re-introduced into the patient. Using this second generation CAR T cell, Dr. Carl June and his colleagues at Penn obtained long-lasting persistence once the cells were re-introduced.
Here is a handy snapshot of how the proposed affordable care act impacts GIST patients.
Caring for someone suffering from an illness is hard, there's no other way to put it. Most of the time it gets easier but in the beginning right after a surgery, it can be very emotionally draining and frightening. Caring for someone you love is even more so as there is an emotional connection, a deep desire to alleviate the pain and suffering we see in the eyes of the person whose bedside we are hovering over.
How does a $2 million-a-year cancer research effort with a team of nine scientists keep pace with a $100 million-a-year project with a team of 200? Pretty well, it turns out. With the Cancer Genome Atlas project in the news lately—the New York Times recently reported on progress in its colon cancer work—we decided to compare some of its data with that of the Life Raft Group’s Research Team and its D-Day Project. Our research focuses on GIST.
Caring for someone suffering from an illness is hard, there’s no other way to put it. Most of the time it gets easier but in the beginning right after a surgery, it can be very emotionally draining and frightening. Caring for someone you love is even more so as there is an emotional connection, a deep desire to alleviate the pain and suffering we see in the eyes of the person whose bedside we are hovering over.
